Juvenile myelomonocytic leukemia: Epidemiology, etiopathogenesis, diagnosis, and management considerations

Pediatric Drugs

Volumn 12, Issue 1, 2010, Pages 11-21

  Yoshimi, Ayami ^a   Kojima, Seiji ^b   Hirano, Naoto ^c  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Children; L 739749, therapeutic use; L 744832, therapeutic use; Myeloid leukaemia, diagnosis; Myeloid leukaemia, pathogenesis; Myeloid leukaemia, treatment; Research and development; Stem cell transplant; Tipifarnib, therapeutic use

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE RECEPTOR ANTAGONIST; DIPHTHERIA TOXIN 388 GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; E 21 R; FLUDARABINE; GERANYLTRANSFERASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; HEMOGLOBIN F; ISOTRETINOIN; K RAS PROTEIN; MELPHALAN; MERCAPTOPURINE; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; NEUROFIBROMIN; PROTEIN FARNESYLTRANSFERASE; PROTEIN GERANYLGERANYLTRANSFERASE TYPE 1; PROTEIN GERANYLGERANYLTRANSFERASE TYPE 2; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAF PROTEIN; RAS PROTEIN; SOS PROTEIN; TIPIFARNIB; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHIMERA; CLINICAL TRIAL; CONCENTRATION RESPONSE; CORD BLOOD STEM CELL TRANSPLANTATION; DIFFERENTIAL DIAGNOSIS; DISEASE FREE SURVIVAL; DONOR; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG TARGETING; EVENT FREE SURVIVAL; FAMILY; GENE MUTATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMOGLOBIN BLOOD LEVEL; HEPATOMEGALY; HUMAN; IN VITRO SELECTION; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA RELAPSE; LEUKOCYTOSIS; LOW DRUG DOSE; LYMPHADENOPATHY; MICROSATELLITE MARKER; MINIMAL RESIDUAL DISEASE; MONOSOMY 7; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NEUROFIBROMATOSIS; NOONAN SYNDROME; ONCOGENE N RAS; PALLOR; PATHOGENESIS; PATIENT MONITORING; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; RECURRENCE RISK; REVIEW; SIGNAL TRANSDUCTION; SPLENECTOMY; SPLENOMEGALY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; GENES, NEUROFIBROMATOSIS 1; GENES, RAS; GENETIC PREDISPOSITION TO DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; PEDIATRICS; POINT MUTATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; RECURRENCE;

EID: 73849112596     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11316200-000000000-00000     Document Type: Review

References (90)

1. Arico M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood 1997; 90 (2): 479-488
2. Niemeyer CM, Arico M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a report of 110 cases. Blood 1997; 89 (10): 3534-3543
3. Emanuel PD. Juvenile myelomonocytic leukemia. Curr Hematol Rep 2004; 3 (3): 203-209
4. Niemeyer CM, Fenu S, Hasle H, et al. Differentiating juvenile myelomonocytic leukemia from infectious disease [letter]. Blood 1998; 91 (1): 365-367
5. Vardiman J, Pierre R, Imbert M, et al. Juvenile yelomonocytic leukemia. In: Jaffe ES, Harris NL, Stein H, et al., editors. Pathology and genetics of tumors of haematopoietic and lympoid tissues: World Health Organization Classification of Tumors. Lyon: IARC Press, 2001: 55-57
6. Luna-Fineman S, Shannon KM, Atwater SK, et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood 1999; 93 (2): 459-466
7. SasakiH,Manabe A, Kojima S, et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia 2001; 15 (11): 1713-1720
8. Xu GF, O'Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990; 62 (3): 599-608
9. DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000; 105 (3 Pt 1): 608-614 (Pubitemid 30129679)
10. Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population- based UKCCSG study. Br J Cancer 1994; 70 (5): 969-972
11. Bader JL, Miller RW. Neurofibromatosis and childhood leukemia. J Pediatr 1978; 92: 925-929
12. Allanson JE. Noonan syndrome. Am J Med Genet C Semin Med Genet 2007; 145 (3): 274-279
13. Bader-Meunier B, Tchernia G, Mielot F, et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr 1997; 130 (6): 885-889
14. Choong K, Freedman MH, Chitayat D, et al. Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol 1999; 21 (6): 523-527
15. Fukuda M, Horibe K, Miyajima Y, et al. Spontaneous remission of juvenile chronic myelomonocytic leukemia in an infant with Noonan syndrome. J Pediatr Hematol Oncol 1997; 19 (2): 177-179
16. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. NatGenet 2001; 29: 465-468
17. Tartaglia M, Pennacchio LA, Zhao C, et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007; 39 (1): 75-79
18. Roberts AE, Araki T, Swanson KD, et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 2007; 39 (1): 70-74
19. Schubbert S, Zenker M, Rowe SL, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006; 38 (3): 331-336
20. Pandit B, Sarkozy A, Pennacchio LA, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007; 39 (8): 1007-1012
21. Razzaque MA, Nishizawa T, Komoike Y, et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 2007; 39 (8): 1013-1017
22. Emanuel PD, Bates LJ, Castleberry RP, et al. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991; 77 (5): 925-929
23. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34 (2): 148-150
24. Miyauchi J, AsadaM, SasakiM, et al. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood 1994; 83 (8): 2248-2254
25. Castro-Malaspina H, Schaison G, Passe S, et al. Subacute and chronic myelomonocytic leukemia in children (juvenile CML): clinical and hematologic observations, and identification of prognostic factors. Cancer 1984; 54 (4): 675-686
26. Passmore SJ, Chessells JM, Kempski H, et al. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a populationbased study of incidence and survival. Br J Haematol 2003; 121 (5): 758-767
27. Side LE, Emanuel PD, Taylor B, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 1998; 92 (1): 267-272
28. Flotho C, Valcamonica S, Mach-Pascual S, et al. RAS mutations and clonality analysis in children with juvenilemyelomonocytic leukemia (JMML). Leukemia 1999; 13 (1): 32-37
29. Satoh T, Nakafuku M, Miyajima A, et al. Involvement of ras p21 protein in signal-transduction pathways from interleukin 2, interleukin 3, and granulocyte/ macrophage colony-stimulating factor, but not from interleukin 4. Proc Natl Acad Sci U S A 1991; 88 (8): 3314-3318
30. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature 1990; 348 (6297): 125-132
31. Matsuda K, Shimada A, Yoshida N, et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood 2007; 109 (12): 5477-5480
32. Chan RJ, FengGS. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 2007; 109 (3): 862-867
33. Hof P, Pluskey S, Dhe-Paganon S, et al. Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998; 92 (4): 441-450
34. Kratz CP, Niemeyer CM, Castleberry RP, et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/ myeloproliferative disease. Blood 2005; 106 (6): 2183-2185
35. Niihori T, Aoki Y, Ohashi H, et al. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. J Hum Genet 2005; 50 (4): 192-202
36. Loh ML, Vattikuti S, Schubbert S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004; 103 (6): 2325-2331
37. Watanabe I, Horiuchi T, Hatta N, et al. Analysis of neurofibromatosis type 1 gene mutation in juvenile chronic myelogenous leukemia. Acta Haematol 1998; 100 (1): 22-25
38. Shannon KM, O'Connell P, Martin G, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant disorders. N Engl J Med 1994; 330: 597-601
39. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996; 12 (2): 144-148
40. Flotho C, Steinemann D, Mullighan CG, et al. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11. Oncogene 2007; 26 (39): 5816-5821
41. Stephens K, Weaver M, Leppig KA, et al. Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanismof NF1 inactivation in myeloid malignancies. Blood 2006; 108 (5): 1684-1689
42. Braun BS, Tuveson DA, Kong N, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A 2004; 101 (2): 597-602
43. Chan IT,Kutok JL, Williams IR, et al. Conditional expression of oncogenicKras from its endogenous promoter induces amyeloproliferative disease. J Clin Invest 2004; 113 (4): 528-538
44. Mohi MG, Williams IR, Dearolf CR, et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 2005; 7 (2): 179-191
45. Largaespada DA, Brannan CI, Jenkins NA, et al. Nf1 deficiency causes Rasmediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 1996; 12 (2): 137-143
46. Le DT, Kong N, Zhu Y, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 2004; 103 (11): 4243-4250
47. Kratz CP, Schubbert S, Bollag G, et al. Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders. Cell Cycle 2006; 5 (15): 1607-1611
48. Noonan JA. Noonan syndrome and related disorders: alterations in growth and puberty. Rev Endocr Metab Disord 2006; 7 (4): 251-255
49. Gelb BD, Tartaglia M. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum Mol Genet 2006; 15 Spec No 2: R220-6
50. Kratz CP, Niemeyer CM, Thomas C, et al. Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia. Leukemia 2007; 21 (5): 1108-1109
51. Tanaka M, Takahashi Y, Xu Y, et al. Quantification of granulocyte-macrophage colony-stimulating factor hypersensitivity in juvenile myelomonocytic leukemia by (3)H-thymidine assay. Leuk Res 2008; 32 (7): 1036-1042
52. Kotecha N, Flores N, Irish J, et al. A novel assay for juvenile myelomonocytic leukemia based on aberrant signaling networks measures via phosphospecific flow cytometry reduces diagnosis time from weeks to days. Blood 2007; 110 (11): 168a
53. Manabe A, Yoshimasu T, Ebihara Y, et al. Viral infections in juvenile myelomonocytic leukemia: prevalence and clinical implications. J Pediatr Hematol Oncol 2004; 26 (10): 636-641
54. Watanabe N, Yoshimi A, Kamachi Y, et al. Wiskott-Aldrich syndrome is an important differential diagnosis in male infants with juvenile myelomonocytic leukemia-like features. J Pediatr Hematol Oncol 2007; 29 (12): 836-838
55. Kuijpers TW, Bruggen R, Kamerbeek N, et al. Natural history and early diagnosis of LAD-1/variant syndrome. Blood 2007; 109 (8): 3529-3537
56. Chan HS, Estrov Z, Weitzman SS, et al. The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia. J Clin Oncol 1987; 5 (12): 1960-1967 (Pubitemid 18010156)
57. DeHeredia CD, Ortega JJ, Coll MT, et al. Results of intensive chemotherapy in children with juvenile chronic myelomonocytic leukemia: a pilot study. Med Pediatr Oncol 1998; 31: 516-520
58. Locatelli F, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 2005; 105 (1): 410-419 (Pubitemid 40053113)
59. Emanuel PD, Zuckerman KS, Wimmer R, et al. In vivo 13-cis retinoic acid therapy decreases the in vitro GM-CSF hypersensitivity in juvenile chronic myelogenous leukemia (JCML). Blood 1991; 78 (10 Suppl.1): 170a
60. Castleberry RP, Emanuel PD, Zuckerman KS, et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia.NEngl J Med 1994; 331 (25): 1680-1684
61. Castelberry RP, Chang M, Maybee D, et al. A phase II study of 13-cis retinoic acid in juvenile myelomonoctic leukemia. Blood 1997; 90: 346a
62. Lutz P, Zix-Kieffer I, Souillet G, et al. Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC children's leukemia cooperative group (CLCG). Bone Marrow Transpl 1996; 18: 1111-1116
63. Bergstraesser E, Hasle H, Rogge T, et al. Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria. Pediatr Blood Cancer 2007; 49 (5): 629-633
64. Pui CH, Arico M. Isotretinoin for juvenile chronic myelogenous leukemia. N Engl J Med 1995; 332: 1520-1521
65. Mutz ID, Zoubek A. Transient response to alpha-interferon in juvenile chronic myelomonocytic leukemia. Pediatr Hematol Oncol 1988; 5: 71-75
66. Suttorp M, Rister M, Schmitz N. Interferon-alpha-2 (IFN) plus hydroxyurea for treatment of juvenile chronic myelogenous leukemia. Med Pediatr Oncol 1994; 22 (5): 358-359
67. Maybee D, Dubowy R, Krischer J, et al. Unusual toxicity of high dose alpha interferon (aIFN) in the treatment of juvenile chronic myelogenous leukemia (JCML). Proc Am Soc Clin Oncol 1992; 1: 950a
68. Manabe A, Okamura J, Yumura-Yagi K, et al. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 2002; 16 (4): 645-649
69. Smith FO, King R, Nelson G, et al. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. Br J Haematol 2002; 116 (3): 716-724
70. Locatelli F, Niemeyer C, Angelucci E, et al. Allogenic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol 1997; 15 (2): 566-573
71. Yabe M, Sako M, Yabe H, et al. A conditioning regimen of busulfan, fludarabine and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia. Pediatr Transplant 2008; 12 (8): 862-867
72. Locatelli F, Madureira A, Rocha V, et al. Unrelated cord blood transplantation for children with juvenile myelomonocytic leukemia [abstract no. 2021]. Blood 2007; 110 (11): 602a
73. Yoshimi A, Niemeyer CM, Bohmer V, et al. Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia. Br J Haematol 2005; 129 (4): 542-549
74. Archambeault S, FloresNJ, YoshimiA, et al. Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. Blood 2008; 111 (3): 1124-1127
75. Yoshimi A, Bader P, Matthes-Martin S, et al. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 2005; 19 (6): 971-977 (Pubitemid 40862007)
76. Hirano N, Butler MO, Xia Z, et al. Identification of an immunogenic CD8+ Tcell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood 2006; 108 (8): 2662-2668
77. YoshimiA,MohamedM, BieringsM, et al. Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia 2007; 21 (3): 556-560
78. Reuter CW, Morgan MA, Bergmann L. Targeting theRas signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000; 96 (5): 1655-1669
79. Emanuel PD, Snyder RC, Wiley T, et al. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood 2000; 95 (2): 639-645
80. Arceci RJ, Longley BJ, Emanuel PD. Atypical cellular disorders. Hematology Am Soc Hematol Educ Program 2002; 297-314
81. Castleberry RP, Loh ML, Jayaprakash N, et al. Phase II window study of the farnesyltransferase inhibitor R115777 (Zarnestra) in untreated juvenile myelomonocytic leukemia (JMML): a Children's Oncology Group study. Blood 2005; 106 (11): 727a
82. Roelofs AJ, Thompson K, Gordon S, et al. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006; 12 (20 Pt 2): 6222-30s
83. Ohtsuka Y, Manabe A, Kawasaki H, et al. RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro. Blood 2005; 106 (9): 3134-3141
84. ShimadaH, ShimaH, ShimasakiN, et al. Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation. Ann Oncol 2005; 16 (8): 1400
85. Liu YL, Castleberry RP, Emanuel PD. Rapamycin: a potential mechanistically targeted therapeutic for juvenile myelomonocytic leukemia. Blood 2004; 104 (11): 653a
86. Iversen PO, Rodwell RL, Pitcher L, et al. Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colony-stimulating factor analogue E21R. Blood 1996; 88 (7): 2634-2639
87. Iversen PO, Turczynowicz S, Lewis J, et al. A second generation GM-CSF analogue that prevents dissemination and induces remission of human juvenile myelomonocytic leukemia in engrafted immunodeficient mice. Blood 1997; 90: 4910-4917
88. Bernard F, Thomas C, Emile JF, et al. Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia. Blood 2002; 99 (7): 2615-2616
89. Frankel AE, Lilly M, Kreitman R, et al. Diphtheria toxin fused to granulocytemacrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Blood 1998; 92 (11): 4279-4286
90. Frankel AE, Powell BL, Hall PD, et al. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 2002; 8 (5): 1004-1013